Free CME from PeerView


Pathology CME

Credits: 1.5 CME / MOC / CC
PVI, PeerView Institute for Medical Education
Parsing the Practicalities of Pathologic Response Assessment After Neoadjuvant Immunotherapy to Facilitate Progress in Early-Stage Cancers
Prof. Solange Peters, MD, PhD
April 10, 2022
Credits: 1.5 CME / MOC / CC
Medical Learning Institute, Inc.
Progress and Practicalities in Immunotherapy Biomarker Testing and Pathologic Response Assessment in Solid Tumors: What’s New and What You Need to Know and Do
Kurt A. Schalper, MD, PhD
March 22, 2022
Credits: 2.0 CME / MOC
Purdue University
Accelerating Progress in the Treatment of Alzheimer’s Disease: How Can We Achieve Timely and Accurate Neuropathological Diagnosis and Precision Management of Mild Cognitive Impairment in Early Alzheimer’s Disease?
Liana G. Apostolova, MS, MD, FAAN
March 18, 2022
Credits: 1.0 CME / MOC
Medical Learning Institute, Inc.
Linking Immunotherapy to Better Outcomes in Resectable Melanoma: Guidance on Integrating Immune-Based Adjuvant and Neoadjuvant Options
Jennifer Wargo, MD, MMSc
March 10, 2022
Stephen V. Liu, MD
Credits: 0.75 CME / MOC
PVI, PeerView Institute for Medical Education
Visual Exploration of the Possibilities for Macrocyclic TKIs in Treatment-Naive and Pretreated Fusion-Positive NSCLC and Other Tumors
Stephen V. Liu, MD
February 18, 2022
Michael Heinrich, MD
Credits: 1.0 CME / MOC / NCPD / CPE
Medical Learning Institute, Inc.
Optimally Sequencing Modern TKIs in GIST: Expert Perspectives From an Interprofessional Sarcoma Team
Michael Heinrich, MD
January 13, 2022
Credits: 0.5 CME / MOC / CC / NCPD / CPE
Medical Learning Institute, Inc.
New Advances and Opportunities for Improvement in HR+/HER2- Early Breast Cancer: Practical Strategies for Optimal Clinical Integration of Adjuvant CDK4 and 6 Inhibitor Therapy
Sara M. Tolaney, MD, MPH
December 28, 2021
Credits: 1 CME / MOC / CC
Medical Learning Institute, Inc.
Time for Even More Precision in Testing and Treatment of EGFR-Mutated NSCLC: Refining and Expanding Best Practices in Advanced and Early-Stage Disease Settings
Lynette M. Sholl, MD
October 29, 2021
Credits: 1.5 CME / MOC / CC
Medical Learning Institute, Inc.
Evolving Standards in Biomarker Testing, Scoring, and Results Interpretation Driven by the Broadening Role of Cancer Immunotherapy
Kurt A. Schalper, MD, PhD
September 29, 2021
Credits: 1 CME / MOC / CC / NCPD
PVI, PeerView Institute for Medical Education
Maximizing the Potential of Immunotherapy in Multimodal Management of Unresectable Stage III NSCLC: Collaboration Is Crucial, Patient Selection Is Paramount, Close Monitoring Is Critical
September 02, 2021
Credits: 1.50 CME / MOC / NCPD
Medical Learning Institute, Inc.
The Expanding Advanced Ovarian Cancer Treatment Palette: Candid Conversations on Bringing PARP Inhibitors Into Clinical Practice
Deborah K. Armstrong, MD
July 06, 2021
Credits: 1.50 CME / MOC / NCPD / CPE
Medical Learning Institute, Inc.
Innovative Immunotherapy in Advanced Basal Cell Carcinoma: Evolving Science, Key Clinical Evidence, and Implications for Multidisciplinary Management
Karl D. Lewis, MD
June 25, 2021
Medical Learning Institute, Inc.
Revisiting PD-L1 as an Immunotherapy Biomarker Across the Cancer Spectrum: Current and Emerging Standards of Testing, Scoring, and Assay Interpretation
Suresh S. Ramalingam, MD, FACP, FASCO
May 11, 2021
Dara L. Aisner, MD, PhD / Joshua Bauml, MD
Medical Learning Institute, Inc.
Precision Decisions in Genomic Testing and Targeted Treatment of NSCLC
Dara L. Aisner, MD, PhD / Joshua Bauml, MD
April 13, 2021
Medical Learning Institute, Inc.
HER2 and HER3 Alterations as Therapeutic Targets of Increasing Significance in Solid Tumors: Implications for Pathology and Oncology Practice
Kurt A. Schalper, MD, PhD
April 06, 2021
Medical Learning Institute, Inc.
New Horizons in EGFR-Mutated NSCLC: Broadening the Impact of Precision Testing in the Context of an Expanding Treatment Landscape
Maria Arcila, MD
January 26, 2021
Medical Learning Institute, Inc.
Navigating the Complexities of Biomarker Testing in the Expanding Field of Precision Immuno-Oncology: Latest Evidence, Current Challenges, and Practical Guidance for Pathologists
Kurt Schalper, MD, PhD
October 16, 2020
Naval Daver, MD / Joseph D. Khoury, MD, FCAP
Medical Learning Institute, Inc.
The Pathology–Oncology Partnership in AML: Identifying and Treating the Diversity of Disease Subtypes
Naval Daver, MD / Joseph D. Khoury, MD, FCAP
October 15, 2020
Medical Learning Institute, Inc.
Modern Diagnostics and Targeted Therapy for TRK Fusion Cancers: Pathology-Oncologist Collaboration in the Era of Precision Medicine
George D. Demetri, MD
July 31, 2020

Upcoming Live Events

Education Collections

Recent CME Podcast

More Podcasts from PeerView